Focused On-demand Library for UV excision repair protein RAD23 homolog A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P54725

UPID:

RD23A_HUMAN

Alternative names:

Alternative UPACC:

P54725; K7ESE3; Q59EU8; Q5M7Z1

Background:

UV excision repair protein RAD23 homolog A plays a pivotal role in cellular mechanisms, acting as a multiubiquitin chain receptor that modulates proteasomal degradation. It exhibits specificity for 'Lys-48'-linked polyubiquitin chains, facilitating the targeted degradation of proteins. Additionally, it is integral to nucleotide excision repair, functioning alongside XPC to repair DNA damage efficiently. Its involvement in the Vpr-dependent replication of HIV-1 highlights its significance in viral pathogenesis.

Therapeutic significance:

Understanding the role of UV excision repair protein RAD23 homolog A could open doors to potential therapeutic strategies. Its critical functions in protein degradation and DNA repair mechanisms position it as a key target for developing treatments for diseases characterized by protein misfolding or DNA damage, as well as for antiviral therapies.